Opko Health, Inc. · NASDAQ:OPK
Opko Health — J.P. Morgan Healthcare Conference 2025
12 slides from Opko Health's conference presentation, Jan 15, 2025
Slide 1: OPKO J.P. Morgan Healthcare Conference
OPKO J.P. Morgan Healthcare Conference January 15, 2025 NASDAQ: OPK
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘hs pnsaton conn raising stent 8 ta tn ed nce a rate Sacre Lion Rees At of 1298 (PSLRA, when set ares ym hee awn tpn abr ea ate hn teh ‘Seung Exergy Caremnuon an ean Dag Rak Fa meu eet ngs wn be Sein ad Exchange Camenaee, Hs he 0 st atanarase nats tens peraactts PARA
Slide 3: 2024 In Review: A Transformative Year
2024 In Review: A Transformative Year OPKO is well-positioned for growth and value across its businesses ‘Therapeutics Pipeline MocleX } Progression + Expansion Enhanced Financial Strength OPKO ) Novel Long-Acting Sioiogics J Biologies Development Restructuring Clinical Diagnostics to Profitability
Slide 4: ModeX Proprietary Technologies
ModexX Proprietary Technologies ‘Since OPKO's acquisition in May 2022, ModeX has further validated its core technologies and advanced 3 pipeline ascets to clinical stages MULTISPECIFIC ANTIBODIES: IMMUNo- Ge, IMMUNOLOGY VIRAL DISEASES
Slide 5: ModeX Development Pipeline
ModeX Development Pipeline ‘ModeX has promising portfolio assets with 3 in clinical stage and 2 pre-IND assets to enter clinic in 2025 P] SR enn A eee | ocean | [| ren tavern ron nn leiees cov MatipeieAnates tone OVO sevuttety tne cece pense (2)
Slide 6: ModeX Partnerships and Business Development
ModexX Partnerships and Business Development OPKO has formed. to share costs and leverage = © merck ® a EBV NANOPARTICLE covin-19 / FLU ADDITIONAL VACCINE MULTISPECIFICS PARTNERSHIPS PH1 TRIAL + Active business development ieee sesmousrecremmesucises *sihebaines dvtgne oo os —— 3872.5 205m + Noa cob
Slide 7: Advancement in Long-Acting Biologics
Advancement in Long-Acting Biologics OPKO Biologics nas 2 robust and portfolio of proteins and peptide drug candidates which have the potential o address large, high-need markets, Y Created NGENLA™ | injectable hGH molecule by Pfizer in over 40 countries: Utize novel technologies to develop next-gen
Slide 8: Growth of Pharmaceutical Product Sales
Growth of Pharmaceutical Product Sales Business lines across the globe generate durable, growing revenues OPKOH=", Soeur Global Health Sales non Sales of ‘Growin ‘CKD Therapy 19s e6:T04 marsin’
Slide 9: Clinical Diagnostics Reset: A Streamlined BioReference
Clinical Diagnostics Reset: A Streamlined BioReference A recalibration of the organization and improved cost structure position BioReterence for profitability in 2025 BioReference’ $297.5 asst salto Lateopascounting fo 2025 GOALS ~S100M 9 annua revenues Continue strategic restructuring Laptocines cl
Slide 10: Realignment of Capital Structure in 2024
Realignment of Capital Structure in 2024 A series of transactions in 2024 to recapitalize the balance sheet provide Hlexibilty o execute long-term plans '$300M esneabiot conernon tun 20512029 ma) NoenArony mirza wn ton tipo Balance Sheet $250M seinen rus ctsion Strongly Positioned for 2025+ Reset $2
Slide 11: 2025 Priorities to Generate Long-Term Value
2025 Priorities to Generate Long-Term Value Focused on execution of strategie priorities (0 produce clinical and financial success FINI «sce stety and cary eticacy data or Pt assets PSMNAIRME «Prepare 2 ational asses to ener cinca development OEE Exons ron inponaaivepannerps on potty ¥ Continsed sva
Slide 12: OPKO
oPKO